Cape Town, South Africa

Arthritis Clinical Trial Centre

Rheumatoid Arthritis

Arthritis

Lupus Nephritis

Nephritis

Baricitinib

Zetomipzomib

LY3009104

Filgotinib

KZR-616

Lilly

Alfasigma

Kezar Life Sciences

condition

allSponsorName

Incyte

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Arthritis Clinical Trial Centre | Cape Town, South Africa

Site insights

Work at this site?

Active trials

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)

Trial sponsors